Inventiva and AbbVie extend agreement to develop RORγ inverse agonists

04-09-2017

Inventiva, a biopharmaceutical company that develops innovative therapies, has announced the extension of an agreement with AbbVie to continue to research and develop orally available RORγ inverse agonists.


Inventiva, AbbVie, Pierre Broqua, biopharmaceutical company, inverse agonist, RORγ, proteins

LSIPR